Original Article

You have full text access to this OnlineOpen article

Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy

  1. Ilene Staff Ph.D.1,†,‡,*,
  2. Andrew Salner M.D.2,
  3. Richard Bohannon Ed.D.1,‡,
  4. Pauline Panatieri R.N., M.A.2,
  5. Rose Maljanian R.N., M.B.A.1,§

Article first published online: 14 OCT 2003

DOI: 10.1002/cncr.11805

Issue

Cancer

Cancer

Volume 98, Issue 11, pages 2335–2343, 1 December 2003

Additional Information

How to Cite

Staff, I., Salner, A., Bohannon, R., Panatieri, P. and Maljanian, R. (2003), Disease-specific symptoms and general quality of life of patients with prostate carcinoma before and after primary three-dimensional conformal radiotherapy. Cancer, 98: 2335–2343. doi: 10.1002/cncr.11805

Author Information

  1. 1

    Institute for Outcomes Research and Evaluation, Hartford Hospital, Hartford, Connecticut

  2. 2

    Helen & Harry Gray Cancer Center, Hartford Hospital, Hartford, Connecticut

  1. †

    Fax: (860) 545-5112

  2. ‡

    Drs. Staff and Bohannon are now with the Research Program, Hartford Hospital, Hartford, Conneticut.

  3. §

    Ms. Maljanian is now with Humana, Inc.

*Research Program, Hartford Hospital, 80 Seymour Street, Hartford, CT 06106

Publication History

  1. Issue published online: 17 NOV 2003
  2. Article first published online: 14 OCT 2003
  3. Manuscript Accepted: 22 AUG 2003
  4. Manuscript Revised: 18 AUG 2003
  5. Manuscript Received: 15 APR 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (95K)

REFERENCES

  • 1
    American Cancer Society. Cancer facts and figures, 2003. Available from URL: http://www.cancer.org/docroot/STT/stt_0.asp [Accessed 3 October 2003].
  • 2
    RiesLAG, EisnerMP, KosaryCL. et al., editors. SEER cancer statistics review, 1975–2000, National Cancer Institute. Available from URL: http://seer.cancer.gov/csr/1975_2000. 2003 [Accessed 3 October 2003].
  • 3
    Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 1995; 154: 2144–2148.
  • 4
    Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet. 1997; 349: 906–910.
  • 5
    Fowler FJ, McNaughton-Collins M, Albertsen PC, Zeitman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000; 283: 3217–3222.
  • 6
    Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what is important. J Gen Intern Med. 2000; 15: 694–701.
    Direct Link:
  • 7
    Echlin KN, Rees CE. Information needs and information-seeking behaviors of men with prostate cancer and their partners: a review of the literature. Cancer Nurs. 2002; 25: 35–41.
  • 8
    Litwin MS, Hays RD, Fink A, et al. Quality of life outcomes in men treated for localized prostate cancer. JAMA. 1995; 273: 129–135.
  • 9
    Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function—the most important disease-specific distress for patients with prostate cancer. Br J Cancer. 1996; 73: 1417–1421.
  • 10
    Adolfsson J, Helgason AR, Dickman P, Steineck G. Urinary and bowel symptoms in men with and without prostate cancer: results from an observational study in the Stockholm area. Eur Urol. 1998; 33: 11–16.
  • 11
    Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999; 91: 1719–1724.
  • 12
    Litwin MS. Health related quality of life in older men without prostate cancer. J Urol. 1999; 161: 1180–1184.
  • 13
    Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998; 16: 275–283.
  • 14
    Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2000; 164: 1973–1977.
  • 15
    Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001; 19: 1619–1628.
  • 16
    Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB. Effect of treatment on quality of life among men with clinically localized prostate cancer. Med Care. 2001; 39: 243–253.
  • 17
    Clark JA, Rieker P, Propert KJ, Talcott JA. Changes in quality of life following treatment for early prostate cancer. Urology. 1999; 53: 161–168.
  • 18
    Jønler M, Nielsen OS, Wolf H. Urinary symptoms, potency and quality of life in patients with localized prostate cancer followed up with deferred treatment. Urology. 1998; 52: 1055–1063.
  • 19
    Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000; 283: 354–360.
  • 20
    Litwin MS, Melmed GY, Nakazon T. Life after radical prostatectomy: a longitudinal study. J Urol. 2001; 166: 587–592.
  • 21
    Hamilton AS, Standord JL, Gilliland FS, et al. Health outcomes after external beam radiation therapy for clinically localized prostate cancer: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001; 19: 2517–2526.
  • 22
    Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL. Validation study of retrospective recall of disease-targeted function: results from the Prostate Cancer Outcomes Study. Med Care. 2000; 38: 847–857.
  • 23
    Beard CJ, Propert KJ, Rieker PP, et al. Complications after treatment with external beam irradiation in early stage prostate cancer patients: a prospective multi-institutional outcomes study. J Clin Oncol. 1997; 15: 223–229.
  • 24
    Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002; 20: 557–566.
  • 25
    Mouraviev V. Neoadjuvant therapy in localized prostate cancer before surgery and radiotherapy. Curr Opin Urol. 1998; 8: 381–386.
  • 26
    Tubaro A. Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Curr Opin Urol. 2000; 10: 258–259.
  • 27
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56: 899–905.
  • 28
    Ware JE. The SF-36 health survey. Boston: Medical Outcomes Trust, 1992.
  • 29
    Ware JE, Kosinski M, Keller SD. SF-36 Health Survey physical and mental summary scales: a user's manual. Boston: The Health Institute, New England Medical Center, 1994.
  • 30
    Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998; 36: 1002–1012.
  • 31
    Lim AJ, Brandon AH, Fiedler J, et al. Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol. 1995; 154: 1420–1425.
  • 32
    Schover LR, Fouladi RT, Warneke CL, et al. Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer. 2002; 95: 1773–1785.
    Direct Link:
View Full Article (HTML) Get PDF (95K)